[Form 3] Edgewise Therapeutics, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. (EWTX) filed an initial ownership report on Form 3 for its Chief Financial Officer, who is an officer of the company but not a director or 10% owner. The event date for this ownership report is 11/10/2025. The filing states in the remarks that no securities are beneficially owned, indicating that the reporting person did not hold Edgewise Therapeutics equity at the time of this Form 3. The form is filed by one reporting person, with the signature provided by an attorney-in-fact under a power of attorney.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nofi Michael

(Last) (First) (Middle)

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/10/2025

3. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ John R. Moore, Attorney-in-Fact for Michael Nofi	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Edgewise Therapeutics (EWTX) Form 3 filing report?

The Form 3 for Edgewise Therapeutics (EWTX) reports the initial beneficial ownership of the company’s Chief Financial Officer as of 11/10/2025, and notes in the remarks that no securities are beneficially owned.

Who is the reporting person in the Edgewise Therapeutics (EWTX) Form 3?

The reporting person is an officer of Edgewise Therapeutics, specifically the Chief Financial Officer, and is not marked as a director or 10% owner.

Does the Edgewise Therapeutics (EWTX) CFO own any company stock according to this Form 3?

No. The remarks section states, "No securities are beneficially owned", indicating that the CFO did not report ownership of Edgewise Therapeutics securities on this Form 3.

What is the event date disclosed in the Edgewise Therapeutics (EWTX) Form 3?

The Form 3 lists 11/10/2025 as the Date of Event Requiring Statement.

Is the Edgewise Therapeutics (EWTX) Form 3 filed by one or multiple reporting persons?

The filing indicates that it is a Form filed by One Reporting Person, not by more than one reporting person.

Who signed the Edgewise Therapeutics (EWTX) Form 3?

The Form 3 is signed as /s/ John R. Moore, Attorney-in-Fact for Michael Nofi, reflecting the use of a power of attorney noted as Exhibit 24 - Power of Attorney.